Ipilimumab is a: (A) Anti CD30 Monoclonal Antibody, (B) PDL1 receptor inhibitor, (C) CTLA4 inhibitor, (D) PTPN22 inhibitor
Answer is C. Ipilimumab and Tremelimumab are CTLA4 inhibitors used in BRAF -ve malignant melanoma.